Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 2/20 | 0.55 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.55 |
| ▸ | NSD2 | O96028 | 8/20 | 0.53 |
| ▸ | MMP12 | P39900 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15345161 | 0.90 | MMP12 (0.63) | MMP12KDM4ERAB9ANPC1PDE3B | |
| SCHEMBL15341888 | 0.84 | CYP11B1 (0.52) | CYP11B1CYP11B2NSD2KDM4ERAB9A | |
| SCHEMBL15345045 | 0.82 | MMP12 (0.46) | CYP11B1CYP11B2NSD2MMP12KDM4E | |
| SCHEMBL19188092 | 0.79 | MMP12 (0.62) | CYP11B1CYP11B2NSD2MMP12KDM4E | |
| SCHEMBL280003 | 0.79 | MMP12 (0.75) | CYP11B1CYP11B2MMP12KDM4ERAB9A | |
| SCHEMBL15344913 | 0.77 | PDE3B (0.58) | CYP11B1CYP11B2MMP12RAB9ANPC1 | |
| SCHEMBL15345177 | 0.74 | MMP12 (0.46) | NSD2MMP12KDM4ERAB9ANPC1 | |
| SCHEMBL24427535 | 0.74 | CYP11B1 (0.55) | CYP11B1CYP11B2NSD2MMP12PDE3B | |
| SCHEMBL15344951 | 0.74 | CYP11B2 (0.59) | CYP11B1CYP11B2PDE3BPDE3A | |
| SCHEMBL24427533 | 0.74 | CYP11B1 (0.55) | CYP11B1CYP11B2NSD2MMP12PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3070081-B1 | BENZOTHIAZOL-6-YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING AN HIV INFECTION | GILEAD SCIENCES INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-01-21 | — | — | US | disclosed |
| US-8987250-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | CYP11B1 20/4885CYP11B2 19/4885NSD2 3209/4885 |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | CYP11B1 20/4885CYP11B2 19/4885NSD2 3209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.